Fig. 3: Prognosis according to NGS-MRD. | Blood Cancer Journal

Fig. 3: Prognosis according to NGS-MRD.

From: Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study

Fig. 3

Prognosis according to NGS status (A–C) and the number of persistent mutations (D–F). p-values are for log-rank tests for Relapse Free Survival and Overall Survival and for Gray test for Cumulative incidence of Relapse. Data were not censored at allogeneic hematopoietic stem cell transplantation. NEG no mutation detected in CR1, DTA detection of only DNMT3A, TET2 or ASXL1 mutation in CR1; other: detection of other mutation than DNMT3A, TET2 or ASXL1 in CR1.

Back to article page